Sugi Predict

Sugi Predict / Compounds / SCHEMBL6165730

SCHEMBL6165730

SCHEMBL6165730

COC(=O)CC[C@@H]1CCCN1C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.43
▸ NPC1 O15118 1/20 0.41
▸ OPRD1 P41143 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ FPR3 P25089 1/20 0.40
▸ FPR2 P25090 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ KDM1A O60341 1/20 0.39
▸ PDE8B O95263 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6165737 1.00 ATM (0.46) ATMSMN1; SMN2HSD17B10NPC1OPRD1
SCHEMBL7989798 0.96 ATM (0.47) ATMSMN1; SMN2HSD17B10NPC1OPRD1
SCHEMBL6157710 0.96 ATM (0.47) ATMSMN1; SMN2HSD17B10NPC1OPRD1
SCHEMBL29039395 0.92 SMN1; SMN2 (0.42) ATMSMN1; SMN2HSD17B10NPC1OPRD1
SCHEMBL29039393 0.92 SMN1; SMN2 (0.42) ATMSMN1; SMN2HSD17B10NPC1OPRD1
SCHEMBL29039237 0.91 SMN1; SMN2 (0.41) ATMSMN1; SMN2HSD17B10NPC1OPRD1
SCHEMBL29039235 0.91 SMN1; SMN2 (0.41) ATMSMN1; SMN2HSD17B10NPC1OPRD1
SCHEMBL702497 0.88 ATM (0.43) ATMSMN1; SMN2HSD17B10OPRD1KDM1A
SCHEMBL16551790 0.86 ATM (0.47) ATMSMN1; SMN2HSD17B10OPRD1ALDH1A1
SCHEMBL6921210 0.86 ATM (0.47) ATMSMN1; SMN2HSD17B10OPRD1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12134609-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-11-05 — — US disclosed
US-20240092760-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-03-21 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
EP-4208452-A1 QUINOLINE CGAS ANTAGONIST COMPOUNDS Immunesensor Therapeutics, Inc. (US) 2023-07-12 — — EP disclosed
CN-116234802-A Quinoline CGAS antagonist compounds 免疫传感器治疗股份有限公司 2023-06-06 — — CN disclosed
US-20230081291-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-03-16 — — US disclosed
CN-114405547-A Metal complexes 利兹大学 2022-04-29 — — CN disclosed
WO-2022051634-A1 QUINOLINE CGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2022-03-10 — — WO disclosed
CN-108368145-B Metal complexes 利兹大学 2021-12-31 — — CN disclosed
US-10246462-B2 Chemokine receptor modulators and uses thereof FLX BIO, INC. (US) 2019-04-02 — — US disclosed
WO-2018049271-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF FLX BIO, INC. (US) 2018-03-15 — — WO disclosed
WO-2015028409-A1 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-03-05 — — WO disclosed
EP-1129070-A4 NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS BRISTOL MYERS SQUIBB CO (US) 2005-03-02 — — EP disclosed
EP-1129070-A1 NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-09-05 — — EP disclosed
US-6228872-B1 PEPTIDE-PROLYL ISOMERASE AND ROTAMASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2001-05-08 — — US disclosed
WO-2000027811-A1 NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2000-05-18 — — WO disclosed
EP-0789571-A4 CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE MERCK & CO INC (US) 1999-04-14 — — EP disclosed
EP-0789571-A1 CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE Merck & Co., Inc. (US) 1997-08-20 — — EP disclosed
US-5629322-A TREATMENT OF NEURODEGENERATIVE DISORDERS, DISORDERS OF GASTROINTESTINAL MOTILITY AND INFLAMMATION MERCK & CO., INC. (US) 1997-05-13 — — US disclosed
WO-1996014844-A1 CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE MERCK & CO., INC. (US) 1996-05-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092760-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS ATM 234/4885SMN1; SMN2 2633/4885HSD17B10 2690/4885
US-10246462-B2 Chemokine receptor modulators and uses thereof ACKR3, CCR5, CXCR3 ATM 4327/4885SMN1; SMN2 4865/4885HSD17B10 2376/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS ATM 234/4885SMN1; SMN2 2633/4885HSD17B10 2690/4885
US-12134609-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS ATM 234/4885SMN1; SMN2 2633/4885HSD17B10 2690/4885
US-20230081291-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS ATM 234/4885SMN1; SMN2 2633/4885HSD17B10 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.